Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival

OMEROS CORP

Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.
Omeros will resubmit the narsoplimab BLA to FDA as soon as possible for first approved TA-TMA therapy.
Expanded access program data: 46% of adults and 50% of children achieved TA-TMA resolution after failing C5 inhibitors.
European marketing authorisation application planned for Q2 2025; additional sensitivity analyses and manuscripts expected early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.